«We wanted to develop a newborn screen for NPC because we know that the earlier we intervene with investigational
treatments in animal models of the disease, the longer the animals live,» said Ory, the Alan A. and Edith L. Wolff Distinguished Professor of Medicine.
Not exact matches
In a novel animal study design that mimicked human clinical trials, researchers at University of California, San Diego School of Medicine report that long - term treatment using a small molecule drug that reduces activity of the brain's stress circuitry significantly reduces Alzheimer's disease (AD) neuropathology and prevents onset of cognitive impairment in a mouse model of the neurodegenerative conditio
In a novel
animal study design that mimicked human clinical trials, researchers at University
of California, San Diego School
of Medicine report that long - term
treatment using a small molecule drug that reduces activity
of the brain's stress circuitry significantly reduces Alzheimer's
disease (AD) neuropathology and prevents onset
of cognitive impairment
in a mouse model of the neurodegenerative conditio
in a mouse
model of the neurodegenerative condition.
«We report here a gene therapy dose - finding study
in a large
animal model of a severe muscle
disease where a single
treatment resulted
in dramatic rescue,» said Childers.
Our finding
of similarity
in clinical progression between human patients and Huntington's
disease monkeys suggests monkeys could become a preclinical, large
animal model for the development
of new
treatments.»
Mizoribine provides effective
treatment of sequential histological change
of arteritis and reduction
of inflammatory cytokines and chemokines
in an
animal model of Kawasaki
disease
Background:
Treatment with HMG - CoA reductase inhibitors («statins») has been variably associated with a reduced risk
of Alzheimer's
disease (AD)
in epidemiologic studies and reduced amyloid - β (Aβ) deposition
in animal models of AD.
Abstract: Background:
Treatment with HMG - CoA reductase inhibitors («statins») has been variably associated with a reduced risk
of Alzheimer's
disease (AD)
in epidemiologic studies and reduced amyloid - β (Aβ) deposition
in animal models of AD.
With all stages
of clinical Lyme
disease having previously been described
in nonhuman primates, this
animal model was selected
in order to most closely mimic human infection and response to
treatment.
There are currently no
disease - modifying
treatments that have been shown to slow the progression or delay the onset
of HD
in humans; however, several compounds have demonstrated promise
in animal models of HD.1 Robust and sensitive markers
of disease progression are required to assess their efficacy
in humans.
Examples
of studies conducted with assistance
of the Center are pre-clinical studies
of orthopedic devices intended for
animal and human use, clinical studies
of treatment and prevention
of respiratory
diseases in horses and
animal clinical trials evaluating the
treatment of bladder cancer
in Scottish Terriers, an
animal model of human bladder cancer.
An important step
in developing effective
treatments for human
disease is finding an effective
animal model of the
disease to test potential therapies.
Although stem cell therapy is fairly new to veterinary medicine, it has been demonstrated to be an effective
treatment in numerous
animal models of disease such as osteoarthritis, tendon repair, fractures, muscular dystrophy, autoimmune problems, and other disorders.